Related Experiment Videos
Combination therapy of infantile spasms with high-dose pyridoxal phosphate and low-dose corticotropin
Insights
A novel combination therapy using high-dose pyridoxal phosphate and low-dose corticotropin shows promise for treating infantile spasms in children. This treatment achieved significant seizure control and improved EEG findings in most patients, with minimal side effects.
Area of Science:
- Pediatric Neurology
- Pharmacology
Background:
- Infantile spasms are a severe form of epilepsy in infants.
- Current treatments for infantile spasms have limitations and potential side effects.
Purpose of the Study:
- To evaluate the efficacy and safety of a new combination therapy for infantile spasms.
- To assess the combination of high-dose pyridoxal phosphate and low-dose corticotropin.
Main Methods:
- 28 children with infantile spasms were treated.
- Initial monotherapy with pyridoxal phosphate was followed by the addition of corticotropin.
- Seizure control, EEG findings, and long-term outcomes were monitored.
Main Results:
- Combination therapy led to seizure freedom in 84% of patients at 1 month post-corticotropin discontinuation.
- 88% showed improved EEG findings.
- The mean time to seizure control was 4.1 days after starting corticotropin.
Conclusions:
- High-dose pyridoxal phosphate combined with low-dose corticotropin is a promising therapeutic option for infantile spasms.
- The treatment demonstrated a high efficacy rate with a favorable safety profile.
- Long-term follow-up indicated sustained seizure control in a significant portion of patients.
Abstract:
A new combination therapy, high-dose pyridoxal phosphate (40 to 50 mg/kg daily) and low-dose corticotropin (0.01 mg [0.4 IU]/kg daily), was tried in 28 children with infantile spasms. Monotherapy with pyridoxal phosphate provided excellent seizure control in three (11%) of the 28 subjects. Corticotropin was subsequently added to the regimen of the remaining 25 patients. At 1 month after discontinuing corticotropin, 21 (84%) of the 25 patients experienced no seizures, and 22 (88%) of the 25 showed improvement in their electroencephalographic findings. The mean interval until achievement of seizure control was 4.1 days after the initiation of corticotropin. The outcome in the 21 patients has been followed for a mean period of 34.9 months (range, 2 to 81 months). Of these 21 patients, six (29%) have had relapses of infantile spasms, and 10 (48%) have experienced normal development. Transient increases in liver enzymes occurred in 14 (50%) of the 28 patients, but none of the patients developed more serious side effects. The investigators conclude that combination therapy with high-dose pyridoxal phosphate and low-dose corticotropin is a promising new therapy.